News
A mismatched haplotype may improve outcomes in second BMT
Mortality risk was highest in patients who had progressive or refractory disease before a second transplant, or who relapsed within 6 months of a...
News
Wider margins may reduce recurrence risk in early breast cancer
SAN ANTONIO – Updated analysis fails to confirm that ‘no-tumor on ink’ is optimal.
News
Enzalutamide plus exemestane improves PFS in HR+ breast cancer subset
SAN ANTONIO – The combo improved outcomes in those who had not received prior endocrine therapy and who were positive for androgen receptor...
News
Lapatinib plus trastuzumab improves outcomes in HER2+ breast cancer
SAN ANTONIO – Results from CALGB 40601 conflict with those from two larger trials that failed to find a benefit for dual HER2 blockade in treating...
News
Axillary node dissection can be avoided with limited SLN involvement
SAN ANTONIO – Long-term follow-up confirms findings at 5 years, that DFS was similar for cohorts randomized to AD or no AD.
News
ERBB2 expression predicts pCR in HER2+ breast cancer
In the phase 3 NeoALTTO trial, the amplification of ERBB2 was shown to be predictive of pCR; its expression was more predictive of pCR.
News
Zika RNA persists in blood components after clearance from plasma
Zika RNA can persist in blood components for about up to 3 months.
News
High rate of arm morbidity in young breast cancer survivors
SAN ANTONIO – A significant rate of arm swelling and decreased range of motion was seen in young breast cancer patients 1 year after surgery.
News
Zika virus testing shows low incidence in donor blood outside of high-infection areas
Several studies show incidence of Zika in donor blood correlated to local incidence of disease.
News
Denmark reinstates ID NAT screening for blood donations
SAN DIEGO – “The Danish government decided not to discontinue NAT because there were almost no savings.”
News
CDK4/6 inhibitors have similar efficacy in older breast cancer patients
SAN ANTONIO – Treatment with CDK4/6 inhibitors appears to have the same efficacy in older breast cancer patients, as compared with younger ones....
News
Adjuvant trastuzumab for 1 year remains standard of care for early HER2+ breast cancer
SAN ANTONIO – The phase 3 SOLD trial failed to show a 9 week course of trastuzumab as noninferior to the standard 12-month course.
News
Acupuncture significantly reduces AI-associated arthralgias
SAN ANTONIO – Women receiving acupuncture had significantly lower joint pain scores in a randomized phase 3 trial.
News
Novel ADC shows promise in metastatic triple-negative breast cancer
SAN ANTONIO – Overall response rate was 34% with sacituzumab govitecan as a single agent among heavily pretreated patients with metastatic TNBC....
News
No benefit to trastuzumab in low HER2 breast cancer
SAN ANTONIO - In a randomized trial of more than 3,000 patients, the five-year IDFS was 89.6% for those who received trastuzumab, compared with 89...